Literature DB >> 14506752

Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis.

Paola Riva1, Francesca Crosti, Francesca Orzan, Leda Dalprà, Pietro Mortini, Antonina Parafioriti, Bianca Pollo, Anna Maria Fuhrman Conti, Monica Miozzo, Lidia Larizza.   

Abstract

Various cytogenetic and molecular findings indicate 1p36 loss as a consistent change in sporadic and inherited chordoma, a rare embryogenetic neoplasm arising from notochord remnants. We studied 27 sporadic chordomas by means of loss of heterozygosity (LOH) of 31 microsatellites localized to the 1p36.32-36.11 region, and restricted the minimal LOH interval shared by 85% of the tumours to 1p36.13. We also used RT-PCR analysis to investigate the role of the candidate genes CASP9, EPH2A, PAX7, DAN and DVL1, which were selected on the basis of the physical mapping of the LOH region and their plausible oncosuppressor function. RT-PCR analysis showed the presence of DAN and PAX7 transcript fragments of the expected size in all of 8 chordoma samples, whereas the CASP9-specific fragment was observed in only 3 and EPH2A was absent in one. Smaller than expected DVL1 transcripts were found in 4 tumours as well as in their normal counterpart (nucleus pulposus), which also showed a typically sized transcript. Sequencing revealed the skipping of 3 exons in the smallest DVL1 fragment, thus leading to a frameshift and predicting a truncated DVL1 gene product. Our study of the largest cohort of chordoma patients recruited so far indicates a common molecular lesion at 1p36.13, and suggests that the CASP9, EPH2A and DVL1 genes may play an onco-suppressing role and be involved in the development of chordoma. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 14506752     DOI: 10.1002/ijc.11421

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study.

Authors:  J Chaudhary; M Schmidt
Journal:  Chromosome Res       Date:  2006-07-12       Impact factor: 5.239

3.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

Review 4.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 5.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

6.  Clonality studies in sacral chordoma.

Authors:  Lance Klingler; Rita Trammell; D Gordon Allan; Merlin G Butler; Herbert S Schwartz
Journal:  Cancer Genet Cytogenet       Date:  2006-11

7.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

8.  Endoscopic Resection of Clival Chordoma: A Tertiary Care Experience.

Authors:  Gifty Zacharias; Khageswar Rout; Swatee Dash
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-11-19

9.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

10.  Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Authors:  Elena Tamborini; Emanuela Virdis; Tiziana Negri; Marta Orsenigo; Silvia Brich; Elena Conca; Alessandro Gronchi; Silvia Stacchiotti; Giacomo Manenti; Paolo G Casali; Marco A Pierotti; Silvana Pilotti
Journal:  Neuro Oncol       Date:  2010-02-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.